Program-Level Neoadjuvant Chemotherapy Use and 10-Year Survival in Advanced Ovarian Cancer - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Neoadjuvant Chemotherapy Strategies and a Decade of Survival Outcomes in Advanced Ovarian Cancer

  • By

  • Alex E. R. Powers

  • Gretchen Davis

  • Deshae Jenkins

  • Alicia Youssef

  • William Manning

  • Jason D. Wright

  • Nancy L. Keating

  • Amy Bregar

  • Alejandro Rauh-Hain

  • Alexander Melamed

  • September 17, 2026

Share

  • 1

    Neoadjuvant chemotherapy (NACT) followed by interval surgery provides similar overall survival to primary debulking surgery with lower perioperative morbidity.

  • 2

    The study analyzed 34,615 patients with advanced ovarian cancer to evaluate the association between NACT adoption and 10-year survival outcomes.

  • 3

    NACT use increased from 20.3% to 22.7% in low-use programs and from 21.5% to 42.8% in high-use programs between 2004-2015.

  • 4

    There was no significant association between NACT adoption and long-term survival probability or life expectancy in the studied programs.

  • 5

    The findings suggest that NACT does not compromise durable survival, aligning with randomized clinical trial evidence on its oncologic effectiveness.

Original Source(s)

Related Content